Urinary dopamine sulfate conjugates in Parkinson’s disease

  • E. Kienzl
  • K. Eichinger
  • K. Jellinger
  • W. Kuhn
  • G. Fuchs
  • W. Danielczyk
  • W. Wesemann
  • P. Riederer
Part of the New Vistas in Drug Research book series (DRUG RESEARCH, volume 1)


Dopamine-3-O-sulfate (DA-3-O-S) and dopamine-4-O-sulfate (DA-4-O-S) have been shown to be important end-products of L-dopa metabolism. Therefore, when measured in urine samples of patients with Parkinson’s disease (PD), they may give indications of disorders in the peripheral metabolism of catecholamines. In addition, information about the reliability of DA sulfation after L-dopa therapy may be of significance in assessing its role in the elimination of DA from the peripheral nervous system.

Although DA-3-O-S seems to be the predominant sulfo-conjugate in urine, it is neither changed in PD compared to controls with or without other neurological disorders nor in depression syndrome. By contrast, DA4-O-S is significantly decreased in de novo PD patients. However, a similar reduction is notable in cases of other neurological disorders. In depressed patients, the loss of this compound is less pronounced as compared to de novo PD patients. Treatment with combined L-dopa therapy increases primarily DA-3-O-S, while changes in DA-4-O-S are only marginal.

It can be concluded that urinary DA-3-O-S cannot be used as a marker for PD, while DA-4-O-S is significantly reduced in a variety of neurological disorders and, in particular, in PD. Further studies are necessary to elucidate its role as possible peripheral marker to distinguish preclinical PD and depression syndrome.


Sulfate Conjugation Dopamine Hydrochloride Depression Syndrome Neurological Disorder Group Decarboxylase Inhibitor Benserazide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arakawa Y, Imai K, Tamura Z (1979) High-performance liquid chromatographic determination of dopamine sulfoconjugates in urine after L-dopa administration. J Chromatogr 162: 311–318PubMedCrossRefGoogle Scholar
  2. Bacopoulos NG, Hattox SE, Roth RH (1979) 3,4-Dihydroxyphenylacetic acid and homovanillic acid in rat plasma: possible indicators of central dopaminergic activity. Eur J Pharmacol 56: 225–236PubMedCrossRefGoogle Scholar
  3. Barbeau A (1961) Biochemistry of Parkinson’s disease. Excerpta Medica, ICS 38: 152–153Google Scholar
  4. Barbeau A (1969) Parkinson’s disease as a systemic disorder. In: Gillingham FJ, Sonaldson ML (eds) 3rd Symposium on Parkinson’s disease. Edinburgh, Livingstone, pp 66–73Google Scholar
  5. Barbeau A (1975) Pathophysiology of the oscillations in performance after long-term therapy with L-dopa. In: Birkmayer W, Hornykiewicz O (eds) Advances in parkinsonism. Editions Roche, Basel, pp 424–434Google Scholar
  6. Birkmayer W, Neumayer E (1972) Die moderne medikamentöse Behandlung des Parkinsonismus. Z Neurol 202: 257–280PubMedCrossRefGoogle Scholar
  7. Bronaugh RL, Mattox SE, Hoehn MM, Murphy RC, Rutledge CO (1975) The separation and identification of dopamine 3-O-sulfate and dopamine 4-O-sulfate in urine of parkinsonian patients. J Pharmacol Exp Ther 195: 441–452PubMedGoogle Scholar
  8. Buu NT (1985) Dopamine sulfoconjugation in the rat brain: regulation by monoamine oxidase. J Neurochem 45: 470–476PubMedCrossRefGoogle Scholar
  9. Buu NT, Duhaime J, Savard C, Truong L, Kuchel O (1981) Presence of conjugated catecholamines in rat brain: a new method of analysis of catecholamine sulfates. J Neurochem 36 (2): 769–772PubMedCrossRefGoogle Scholar
  10. Carmichael SW, Wilson RJ, Brimijoin WS, et al (1988) Decreased catecholamine levels in the adrenal medulla of patients with Parkinson’s disease. N Engl J Med 319: 254–256Google Scholar
  11. Corneille L, Lachance S, Demassieux S, Carrière S (1983) Turnover of free and conjugated serum catecholamines during haemodialysis. Clin Invest Med 6: 11–17PubMedGoogle Scholar
  12. Demassieux S, Bordeleau L, Gravel D, Carrière S (1987) Catecholamine sulfates: end-products or metabolic intermediates? Life Sci 40: 183–191PubMedCrossRefGoogle Scholar
  13. Elchisak MA (1983a) Determination of conjugated compounds by liquid chromatography with electrochemical detection using postcolumn hydrolysis. J Chromatogr 255: 475–482CrossRefGoogle Scholar
  14. Elchisak MA (1983b) Determination of dopamine-O-sulfate and norepinephrine-O-sulfate isomers and serotonine-O-sulfate by high-performance liquid chromatography using dual-electrode electrochemical detection. J Chromatogr 264: 119–127CrossRefGoogle Scholar
  15. Elchisak MA (1987) Analytical techniques for the determination of phenolic amine neurotransmitter conjugates. Life Sci 41: 913–916PubMedCrossRefGoogle Scholar
  16. Elchisak MA, Carlson JN (1982) Method for analysis of dopamine sulfate isomers by high-performance liquid chromatography. Life Sci 30: 2325–2336PubMedCrossRefGoogle Scholar
  17. Elsworth JD, Leahy DJ, Roth RH, Redmond jr DE (1986) Homovanillic acid concentrations in brain, CSF and plasma as indicators of central dopamine function in primates. J Neural Transm 68: 51–62CrossRefGoogle Scholar
  18. Foldes A, Meek JL (1974) Occurrence and localisation of brain phenosulfotransferase. J Neurochem 23: 303–307PubMedCrossRefGoogle Scholar
  19. Glover V, Lees AJ, Ward C, Stern GM, Sandler M (1983) Platelet phenosulfotransferase activity in Parkinson’s disease. J Neural Transm 57: 95–102PubMedCrossRefGoogle Scholar
  20. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427–442PubMedGoogle Scholar
  21. Jellinger K (1989) Pathology of Parkinson’s syndrome. In: Caine DB (ed) Handbook of experimental pharmacology, vol 88. Springer, Berlin Heidelberg New York, pp 47–112Google Scholar
  22. Jenner WN, Rose FA (1973) Studies on the sulphation of 3,4-dihydroxyphenylethylamine (dopamine) and related compounds by rat tissues. Biochem J 135: 109–114PubMedGoogle Scholar
  23. Kienzl E, Eichinger K (1988) Preparation of dopamine 3-O-sulfate and dopamine 4-O-sulfate as reference substances and high-performance liquid chromatographic trace determination. J Chromatogr 430: 263–269PubMedCrossRefGoogle Scholar
  24. Krijgsheld KR, Scholtens E, Mulder GJ (1982) The dependence of the rate of sulfate conjugation on the plasma concentration of inorganic sulfate in the rat in vivo. Biochem Pharmacol 31: 3997–4000PubMedCrossRefGoogle Scholar
  25. Kuchel O, Hausser C, Buu NT, Tenneson S (1985) CSF sulfoconjugated catecholamines in man: their relationship with plasma catecholamines. J Neural Transm 62: 91–97PubMedCrossRefGoogle Scholar
  26. Lackovic Z, Relja M, Neff NH (1982) Catabolism of endogenous dopamine in peripheral tissues: is there an independent role for dopamine in peripheral neurotransmission? J Neurochem 38: 1453–1458PubMedCrossRefGoogle Scholar
  27. Renskers KJ, Feor KD, Roth JA (1980) Sulfation of dopamine and other biogenic amines by human brain sulfotransferase. J Neurochem 34: 1362–1368PubMedCrossRefGoogle Scholar
  28. Riederer P, Rausch WD, Birkmayer W, Jellinger K, Seemann D (1978) CNS modulation of adrenal tyrosine hydroxylase in Parkinson’s disease and metabolic encephalopathies. J Neural Transm [Suppl] 141: 121–131Google Scholar
  29. Rivett AJ, Eddy BJ, Roth JA (1982) Contribution of sulfate conjugation, deamination and O-methylation to metabolism of dopamine and nor-epinephrine in human brain. J Neurochem 39: 1009–1016PubMedCrossRefGoogle Scholar
  30. Rivett AJ, Francis A, Whittemore R, Roth JA (1984) Sulfate conjugation of dopamine in rat brain: regional distribution of activity and evidence for neuronal localisation. J Neurochem 42: 1444–1448PubMedCrossRefGoogle Scholar
  31. Rutledge CO, Hoehn MM (1973) Sulfate conjugation and L-dopa treatment of parkinsonian patients. Nature 244: 447–450PubMedCrossRefGoogle Scholar
  32. Scott MC, Elchisak MA (1983) Cardiovascular effects of dopamine sulfate in anesthetized dogs. Fed Proc 42: 13–63Google Scholar
  33. Scott MC, Elchisak MA (1987) Direct measurement of dopamine-O-sulfate in plasma and cerebrospinal fluid. J Chromatogr 413: 17–23PubMedCrossRefGoogle Scholar
  34. Sullivan JM, Nakano KK, Tyler HR (1973) Plasma renin activity during levodopa therapy. Significance of long-and short-term treatment. J Am Med Assoc 224: 1726–1727CrossRefGoogle Scholar
  35. Tyce GM, Rorie DK (1982) Conjugated dopamine in superfusates of slices of rat striatum. J Neurochem 39: 1333–1339PubMedCrossRefGoogle Scholar
  36. Tyce GM, Messick JM, Yaksh TL, Byer DE, Danielson DR, Rorie DK (1986) Amine sulfate formation in the central nervous system. Fed Proc 45 (8): 2247–2253PubMedGoogle Scholar
  37. Van Loon GR (1980) Abnormal catecholamine mechanisms in hypothalamic-pituitary disorders. Metabolism 29 [Suppl] 1: 1198–1202PubMedCrossRefGoogle Scholar
  38. Van Loon GR (1983) Plasma dopamine: regulation and significance. Fed Proc 42: 3012–3018PubMedGoogle Scholar
  39. Van Loon GR, Sole MJ, Bain J (1979) Effects of bromocriptine on plasma catecholamines in normal men. Neuroendocrinology 28: 425–434PubMedCrossRefGoogle Scholar
  40. Weinshilboum RM (1986) Phenol sulfotransferase in humans: properties, regulation and function. Fed Proc 45: 2223–2228PubMedGoogle Scholar
  41. Westerink BHC, ten Kate N (1986) 24 h excretion patterns of free, conjugated and methylated catecholamines in man. J Clin Chem Clin Biochem 24: 513–519PubMedGoogle Scholar
  42. Yamamoto T, Yamatodani A, Nishimura AM (1985) Determination of dopamine-3- and -4-O-sulfate in human plasma and urine by anion-exchange high-performance liquid chromatography with fluorimetric detection. J Chromatogr 342: 261–267PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1990

Authors and Affiliations

  • E. Kienzl
    • 1
  • K. Eichinger
    • 2
  • K. Jellinger
    • 1
  • W. Kuhn
    • 3
  • G. Fuchs
    • 4
  • W. Danielczyk
    • 5
  • W. Wesemann
    • 6
  • P. Riederer
    • 7
  1. 1.Ludwig-Boltzmann-Institute of Clinical NeurobiologyLainz-HospitalViennaAustria
  2. 2.Division of Chromatography and Spectroscopy, Institute of Organic ChemistryTechnical UniversityViennaAustria
  3. 3.Department of NeurologyUniversity of WürzburgGermany
  4. 4.WohlfahrtParkinson ClinicFederal Republic of Germany
  5. 5.Department of NeurologyLainz Geriatric HospitalViennaAustria
  6. 6.Department of Neurochemistry, Institute of Physiology IIUniversity of MarburgGermany
  7. 7.Clinical Neurochemistry, Department of PsychiatryUniversity of Würzburg School of MedicineFederal Republic of Germany

Personalised recommendations